International Journal of Radiation Oncology, Biology, Physics 1994: Vol 28 Index

9 Pages·1994·2.4 MB·English

AUTHOR INDEX
Volume 28, 1994
Abrams, R. A., 1017, 1047 Blue, T. E., 1157 Coughlin, C. T., 1029 Flickinger, J. C., 797
Adelson, J., 105 Bohndorf, W., 387 Cowan, K. H., 395 Foley, J. F., 207
Ahern, V., 867 Bonner, J. A., 363 Cox, R.S., 17, 23, 85, 93, 229, 327 Fomin, S. D., 703
Aizawa, O., 1143 Bortfeld, T. R., 723 Coy, P., 355 Fontanesi, J., 493
Alden, M. E., 945 Bosch, C., 867 Craven, T. E., 349 Foo, D.-L., 457
Alexander, III, E., 1229 Bourland, J. D., 471 Curran, B. H., 1001 Fornander, T., 1235
Allen, B. J., 1183 Bova, F. J., 523, 803, 1047 Curran, Jr., W. J., 549 Fowler, J., 784
Alth, G., 463 Boxwala, A. A., 1009 Fowler, S., 445
American Association of Neurological Boyages, J., 867 D’Angelo, T., 395 Fraass, B. A., 277, 575
Surgeons, Task Force on Stereotac- Boyer, A. L., 723 Dale, J., 613 Fragomeni, R., 515
tic Radiosurgery, 527 Braban, L. E., 563 Davis, L. W., 47 Freedman, A., 1067
American Society for Therapeutic Ra- Brabbins, D., 67 Deasy, J., 784 Friedman, N. D., 829
diology and Oncology, Task Force Brada, M., 405, 553 DeHaan, C. E., 1099 Friedman, W. A., 803, 1047
on Stereotactic Radiosurgery, 527 Brahme, A., 785 Denham, J. W., 731 Fuks, Z., 7, 55, 327, 985, 1219
Amichetti, 163 Braverman, I. M., 829 Deshmukh, A., 101 Fulcrand, G., 1113
Anderson, L., 971 Brenner, D. J., 1039 Deshpande, D. D., 499 Fuller, B. G., 229
Anikin, V. A., 703 Brewer, Y., 1251 Dewhirst, M. W., 415
Anisuzzaman, A. K. M., 1203 Brezovich, I. A., 1025 Dillehay, L. E., 505 Gabel, D., 1175
Antoniades, J., 783 Britten, R. A., 913 Dinshaw, K. A., 499 Gahbauer, R. A., 1157
Aref, A., 467 Brizel, D. M., 213 Diokno, A., 67 Garton, G., 67
Armour, E. P., 171 Bronk, M., 105 Dixon, P., 355 Gash, D., 1067
Arnold, A., 355 Brossard, S., 1135 Dodge, R. K., 213, 415 Gauwitz, M. D., 821
Arterbery, V. E., 985 Brown, J. M., 145, 661 Dominique, C., 343 Gavin, P. R., 1099
Asbell, S. O., 39 Browning, P. G., 913 Donaldson, S. S., 77, 85 Gelman, R., 303
Ashley, S., 405 Brugger, R. M., 1149 Dorie, M. J., 145 Gentile, F. P., 515
Auger, E. A., 179 Buchholz, T. A., 784, 1135 Dorn, III, R. V., 1189 Georgiou, A., 811
Ayoub, J., 355 Biinemann, C., 583 Dover, J. D., 935 Gerner, E. W., 891
Ayyangar, K. M., 979 Biinemann, H., 583 Dunbar, S. F., 1229 Geyer, E., 189
Burman, C. M., 55 Dutreix, A., 285 Ghoshal, S., 335
Baggs, R., 621 Burnison, C. M., 47 Giaccia, A. J., 661
Bagshaw, M. A., 17, 23, 151 Buswell, L., 201 Eapen, L., 531 Gilbert, L., 395
Bailey, M. Q., 1079, 1089 Butler, E. B., 247, 263 Earle, J. D., 207 Gildenberg, P., 247
Bar-Deroma, R., 749 Edmundson, G., 67 Gindrey-Vie, B., 343
Barker, E. A., 395 Caplan, R. J., 47 Edwards, M. S. B., 425 Glatstein, E., 315, 395
Barnes, P. D., 1229 Carlens, P., 1235 Eifel, P. J., 113 Gliick, S., 877
Barraclough, B., 867 Carpino, S., 515 Eisert, D., 523 Goel, R., 531
Barth, R. F., 1057, 1059, 1079, 1089, Carroll, P. R., 33 El Kattan, Y., 1113 Goffinet, D. R., 151, 221, 251
1203 Castro, J. R., 257 El-Naggar, A. K., 821 Gonzalez, J., 67
Bartholomew, R. M., 505 Chang, L.-F. L., 589 Elyan, S., 405 Goodman, M. L., 797
Bauer-Kirpes, B., 481 Chapman, D. S., 55 Engin, K., 935 Goodrich, A. L., 829
Beard, C. J., 303 Charles, H. C., 415 Engler, M. J., 1001 Goris, M. L., 119
Beattie, E. J., 719 Chauvet, B., 1251 Epenetos, A. A., 1257 Goudgaon, N. M., 1113
Beck-Bornholdt, H.-P., 583 Chen, E. Y., 661 Epstein, J. B., 693 Grado, G. L., 439
Bedrosian, C. L., 213 Chen, P. Y., 171 Erickson, B. A., 905 Grant, III, W., 247
Begnozzi, L., 515 Chiatti, L., 515 Evans, M. D. C., 1243 Greenberg, D. D., 1149
Behar, R. A., 221 Chobe, R. J., 101 Evans, W. K., 355 Gregg, D., 105
Belkacemi, Y., 343 Choy, D., 457 Ezzell, G., 467 Griebenow, M. L., 1099
Ben-Yosef, R., 151 Clark, B. G., 1243 Griffin, T. W., 47, 1135
Benassi, M., 515 Cleary, S. F., 77 Fairbanks, R. K., 363 Grigsby, P. W., 451, 1271
Benson, R., 67 Cline, J. M., 649, 921 Febo, R., 1219 Gunderson, L. L., 201
Berger, A., 189 Coderre, J. A., 1067, 1079, 1107, 1167 Fee, Jr., W. E., 221 Gupta, B. D., 335
Bergin, C. J., 93 Coffey, R. J., 797 Feld, R., 355 Gupta, N., 1157
Berner, B., 247 Cogen, P. H., 425 Feldman, A. M., 829 Gyenes, G., 1235
Bernstein, M. J., 373 Coleman, C. N., 201, 303, 321 Félix-Faure, C., 1251
Berson, A. M., 719 Coleman, L., 33 Fessenden, P., 151 Habermann, T. M., 363
Bezwoda, W. R., 613 Contreras, L., 891 Fine, R. L., 213 Habrand, J.-L., 381
Bitar, N., 105 Cooper, D. L., 829 Finkelstein, J. N., 621 Hae-Sook, Y., 33
Bjarngard, B. E., 749 Corrao, A., 749 Fish, B. L., 883 Hahn, G. M., 179
Bjordal, K., 847 Corry, P. M., 171 Fisher, S. R., 213 Halberg, F. E., 201
Bjurstrom, T., 213 Cosmatis, D., 201 Flick, M. B., 135 Hall, E. J., 1039
Hamilton, C. S., 731 Kharazi, A. I., 641 Lorenz, W. J., 481 Mohan, R., 55, 1219
Hamlet, S., 467 Kim, B. S., 711 LoSasso, T. J., 55, 1219 Mohiuddin, M., 945
Hancock, S. L., 93 Kim, G. E., 711 Lubinski, J. M., 641 Molepo, J. M., 531
Hanks, G. E., 39, 201 Kim, H., 373 Lunsford, L. D., 797 Monro, P., 405
Hanlon, A. L., 39 Kim, M. W., 711 Lutz, W., 523 Montpetit, V. A. J., 531
Hansen, J., 1067 Kim, R. Y., 1025 Moore, D. E., 1183
Hao, Y., 563 Kim, W. H., 711 Ma, H.-K., 457 Moravek, J., 1113
Harari, P. M., 891 Kinsella, T. J., 891 Macio, I., 105 Morris, G. M., 1107
Haritz, D., 1175 Kiricuta, I. C., 387 Mackie, R., 784 Morris, M., 113
Harrelson, J. M., 415 Klein, E. E., 753 Mackie, T. R., 1001 Morton, I. E., 913
Harrison, L., 985 Kleinberg, L., 985 MacPhail, P., 613 Moulder, J. E., 883, 905
Harsh, IV, G. R., 797 Kline, R., 523 Mageras, G. S., 1219 Mulkern, R. V., 1229
Hartmann, G. H., 481 Knox, S. J., 119, 445 Mah, K., 563 Murray, N., 355
Harvey, J. C., 719 Koestner, A., 1089 Maity, A., 135 Muschel, R. J., 135
Haston, C. K., 633 Koh, W.-J., 557 Mak, A. C., 597
Hatanaka, H., 1061 KGlbl, O., 387 Mak, J. Y., 425 Nagorney, D. M., 201
Hauptman, H. M., 1149 Komaki, R., 899 Makinodan, T., 641 Nakagawa, Y., 1061, 1217
Hayhurst, E., 105 Kondziolka, D., 797 Mallesch, J. L., 1183 Nakamura, L. T., 641
Hazuka, M. B., 575, 857 Koong, A. C., 661 Maor, M. H., 47 Narayan, P., 33
Healy, J. B., 554 Kooy, H. M., 551, 1229 Maples, W. J., 439 Navvab, Z., 33
Heilmann, H.-P., 583 Koren, H., 463 Marcus, Jr., R. B., 556 Negi, P. S., 335
Heimann, R., 55 Kostashuk, E., 355 Markiewicz, D. A., 135 Nehru, R. M., 499
Herman, M. G., 1017, 1047 Kraft, S. L., 1099 Marks, L. B., 553, 777 Newcomb, C. H., 633
Hill, R. P., 633 Krall, J. M., 39 Maroun, J., 355 Ngan, H. Y. S., 457
Hitchon, H. D., 935 Krook, J. E., 207 Marquez, C., 33, 445 Nigg, D. W., 1121
Hodson, D. I., 355, 839 Kucik, N. A., 373 Marquez, C. M., 425 North Florida Pterygium Study Group,
Holmes, T., 784 Kun, L., 493 Marschke, Jr., R. F., 439 101
Holupka, E. J., 1229 Kuruvilla, A., 101 Martel, M. K., 277, 575, 857 Noyes, R. D., 201
Hong, W. K., 543 Kutcher, G. J., 55, 327, 1219 Martenson, Jr., J. A., 439 Nseyo, U. O., 33
Hopewell, J. W., 1089, 1107 Kuten, A., 613 Martin, P. J., 221
Hopkins, K. L., 93 Kvols, L. K., 207 Martin, W. D., 991 O’Brien, P. C., 683
Hoppe, R. T., 445 Martinez, A., 67, 171 Ochran, T. G., 667
Horvath, J., 589 Lai, P. P., 373 Marzoni, A., 105 Olds, W. W., 349
Hu, J.-P., 1149 Lakier, R., 613 Mason, K. A., 667 Oleson, J. R., 415
Huang, A., 213 Lancaster, S. E., 784 Mason, W. P., 1001 Omarov, A. A., 703
Hudgins, W. R., 797 Langlands, A., 867 Mastekaasa, A., 847 Orazem, J. P., 55
Huiskamp, R., 1175 Laramore, G. E., 47, 1135 Masterson, M. E., 1219 Ostwald, P. M., 731
Larson, D. A., 523, 797 Matalka, K. Z., 1079, 1089 Oswald, M. J., 113
Inwards, C. Y., 363 Larsson, L. G., 1219 Mayer, R. R., 505, 1017, 1047 Ota, D. M., 597
Ito, H., 899 Laugier, A., 343 McCarthy, W. H., 1183 Otterson, M. F., 905
Ivanova, L. F., 703 LaVigne, M. L., 277 McClenathan, J., 105 Owen, J. B., 39
Ivanov, V. N., 703 Lawton, C. A., 883 McCollough, K. P., 471 Ozsahin, M., 343
Leavitt, D. D., 297 McComas, V., 263
Jacky, J., 1135 Lee, A. S., 661 McCunniff, A. J., 349 Page, R. L., 415, 1029
James, S. J., 641 Lee, H. K., 811 McEntee, M. C., 649 Palta, J., 493, 523
Janjan, N. A., 667, 773 Lee, J. S., 543 McGann, J. K., 119 Panella, T. J., 213
Jindra, R. H., 463 Lee, J. T., 711 McKenna, P. J., 207 Papavasiliou, C., 605
Joel, D. D., 1067, 1167 Leeper, D. B., 935 McKenna, W. G., 135 Pareek, P. N., 1025
Johnson, D. W., 101 Lefkopoulos, D., 343 McShan, D. L., 277 Park, Y.-M. K., 179
Johnson, J. M., 741 Leibel, S. A., 7, 55, 327, 1219 Medvedev, V. S., 703 Paryani, S. B., 101
Johnston, C. J., 621 Leopold, K. A., 213, 415 Mehta, M., 523 Patel, F. D., 335
Jones, G. W., 839 Lesnikowski, Z., 1113 Meigooni, A. S., 953 Pater, J. L., 355
Jones, R., 1183 Leunens, G., 285 Melian, E., 55 Pawlicki, T., 979
Joreskog, E., 1219 Levitt, M., 355 Mendenhall, N. P., 556 Payne, D. G., 355
Li, D.-J., 935 Mendenhall, W. M., 556, 803, 1047 Peacock, J. H., 913
Kaasa, S., 847 Li, G. C., 425 Menke, D., 145 Pene, F., 343
Kacinski, B. M., 829 Li, Z., 953 Merino, M. J., 395 Perera, H., 953
Kahler, D. L., 723 Lichter, A. S., 575, 857 Messner, H. A., 877 Perez, C. A., 373, 451, 811
Kalifa, C., 381 Ling, C. C., 55, 971, 1219 Metcalfe, P. E., 731 Petereit, D. G., 891
Kallman, R. F., 761 Ling, S.-S., 589 Micca, P., 1107 Peyton, W., 589
Kantoff, P. W., 303 Link, M. P., 77 Michaletz-Lorenz, M., 753 Phillips, M., 1135
Kaplan, I. D., 17, 23, 257, 327 Liotta, D. C., 1113 Milas, L., 899 Phillips, T. L., 257, 267, 325, 425,
Kapp, D. S., 151, 189, 229 Liu, H. B., 1149, 1167 Min, J. S., 711 1215
Kapp, K. S., 189 Livesey, J. C., 1135 Minchinton, A. I., 119 Pickart, M. A., 891
Kavanagh, B., 597 Lo, Y.-C., 55 Mishra, S., 699, 719 Pickett, B., 267
Keane, T. J., 557, 563 Lockett, M. A., 811 Mishra, V., 953 Pickuth, D., 405
Kenan, P. D., 213 Loeffler, J. S., 523, 1229 Mivechi, N. F., 179 Pierce, L. J., 395
Khan, F. M., 741 Loh, J. J. K., 711 Moeschberger, M. L., 1079 Pilepich, M. V., 39
XVI
Pisch, J., 719 Sandler, H. M., 857 Stuecklschweiger, G., 189 von Eschenbach, A. C., 821
Pistenmaa, D. A., 315 Sarna, S. K., 905 Su, J., 363 Vtyurin, B. M., 703
Pla, C., 1243 Sarrazin, D., 381 Suh, C. O., 711
Pollack, A., 821 Saw, C. B., 979 Sutherland, W. R., 119 Waldron, T. J., 723
Pollock, R., 773 Schell, M. C., 551 Swartz, C. D., 1099 Wall, T. J., 1267
Poon, P. Y., 563 Schenk, G. M., 463 Waller, E. K., 119
Popovic, P., 531 Schewe, K., 523 Wallner, K., 971, 985
Tadros, A., 839
Prados, M. D., 431 Schilling, P. J., 1267 Wambersie, A., 1157
Tarbell, N. J., 1229
Prescott, D. M., 415 Schinazi, R. F., 1113 Wang, Z., 171
Taulelle, M., 1251
Prestidge, B. R., 17, 263 Schlienger, M., 343 Wara, W. M., 431
Taylor, J. M. G., 641
Prionas, S. D., 151 Schoeppel, S., 101 Warenius, H. M., 913
Taylor, K. D., 531
Prosnitz, L. R., 213, 777 Schoeppel, S. L., 277 Wasserman, T. H., 373
Taylor, M., 753
Schray, M., 67 Wazer, D. E., 1001
Taylor, M. E., 47
Raaphorst, G. P., 531 Schultheiss, T. E., 597 Weiner, R., 797
Ten Haken, R. K., 575
Rajan, B., 405 Schultz, C., 523 Wells, Jr., J. W., 101
Terrier-Lacombe, M.-J., 381
Raleigh, J. A., 649, 921 Schutt, A. J., 207, 439 Whitehouse, E. M., 1107
Terry, N. H. A., 821
Randall, M. E., 349 Schwartz, L. H., 343 Whitmore, Jr., W. F., 7
Thames, H. D., 667
Ray, G. R., 105 Scidmore, N. S., 93 Wieand, H. S., 207
Thistlethwaite, A. J., 935
Rebeiro, E., 773 Scott, W. P., 101 Wierzbicki, R., 355
Thomas, G. M., 547
Reboul, F., 1251 Selles, W. D., 1001 Wilbur, D. S., 1135
Thomas, Jr., C., 557
Rekacewicz, C., 381 Seong, J. S., 711 Wilder, R. B., 119
Thoms, Jr., W. W., 113
Rey, A., 381 Serago, C. F., 481 Wilkie, D. A., 1089
Thornton, A. F., 857
Rich, T. A., 597 Shah, K. J., 991 Williams, J. R., 505
Thorson, B., 839
Richmond, R. C., 1029 Shalev, S., 1043 Williamson, J. F., 953
Thrall, D. E., 415, 649, 921
Risler, R., 1135 Sham, J., 457 Willman, K. Y., 85
Tjarks, W., 1203
Roa, W. H. Y., 857 Shao, Y., 505 Willner, J., 387
Touboul, E., 343
Roach, III, M., 33, 267 Sharma, S. C., 335 Willson, K., 683
Traish, D., 405
Roberts, J., 839 Shaw, D., 263 Wilson, J. F., 523
Trembly, B. S., 673
Roberts, J. A., 277 Shaw, E. G., 523, 797 Wilson, K., 355
Tsai, J.-S., 1001
Rockwell, S., 127 Shin, H. S., 711 Wilson, L. D., 829
Tschetter, L. K., 207
Rofstad, E. K., 1079 Shrieve, D. C., 1251 Wiseberg, J. A., 55
Tsirakis, B., 1219
Roh, J. K., 711 Shrivastava, S. K., 499 Wolf, G. T., 857
Tucker, J. A., 415
Rojan, B., 553 Sigmon, W. R., 349 Womack, T., 213
Tupchong, L., 935
Roman, T. N., 1243 Slatkin, D. N., 1167 Wong, F. L. W., 693
Turrisi, A. T., 575, 857
Romsdahl, M. M., 597 Smith, T. L., 113 Wong, P. T. T., 531
Twito, D. I., 207
Rong, F.-G., 1203 Smitt, M. C., 251 Wong, R. L. C., 457
Roos, D. E., 683 Sneed, P. K., 425, 797 Wong, T. Z., 673
Rorer, D. C., 1149 Snook D., 1257 Ullas, G., 1113 Woo, S., 247
Rosenman, J. G., 1009 Soloway, A. H., 1057, 1059, 1079, Umfleet, W., 753 Wooding, Jr., T. S., 1067
Rosenthal, D., 839 1203 Unni, K. K., 363 Wootton, P., 1135
Rosenthal, D. I., 315 Song, S., 505 Urba, S., 857 Wright, J., 683
Rosenthal, S. A., 267 Sostman, H. D., 415 Uzal, C., 343 Wu, A., 979
Rosner, G. L., 921 Souhami, L., 1243 Wu, P.-M., 457
Rousseau, P., 381 Speiser, B. L., 781 Wiirschmidt, F., 583
Rowlinson-Busza, G., 1257 Spencer, D., 613 Valdagni, R., 163 Wyzlic, I. M., 1203
Roy, J., 971, 985 Spencer, S. A., 1025 Van Dam, J., 285
Rubin, P., 1, 3, 333, 561, 621, 795, St. Clair, W. H., 349 Van der Schueren, E., 285 Yeung, D., 493
1055, 1067 Staubus, A. E., 1079 Van Dyk, J., 563, 633, 877
Ruifrok, A. C. C., 667 Stein, M. E., 613 van Herk, M., 1229 Zagars, G. K., 821
Russell, K. J., 47 Steinberg, S. M., 395 Verhey, L., 267 Zaghloul, M. S., 783
Rutqvist, L. E., 1235 Stening, W. A., 1183 Verma, A. K., 891 Zee, B., 355
Sternick, E. S., 1001 Vest, M. L., 451 Zelefsky, M. J., 7, 55, 327, 985
Sadura, A., 355 Stewart, D. J., 531 Vikram, B., 699 Zhang, Y.-G., 505
Sahoo, N., 971 Stewart, J. R., 297 Vincent, P., 1251 Zincke, H., 67
Sailor, T., 1001 Strickler, J. G., 363 Viswanathan, P. S., 499 Zink, S., 47
Salter, M. M., 1025 Stromberg, J., 67 Vitu-Loas, L., 343 Zoeller, D., 753
XVII

SUBJECT INDEX
Volume 28, 1994
A Brain, 1089, 1099 Cataract incidence, 343
Neoplasm, 431 CCI-103F, 649
Tumor(s), 1167, 531 Cell lines
Absorbable mesh, 719 Breast, 753 Human, 913
Absorbed dose, 1143 Treatment, 297 Human myeloma, 877
Accuracy, 481 Breast cancer, 285, 387, 395 C-erb B-2 amplification, 395
Acoustic, 803 Early, 1235 Cervical cancer, 451
Acute effect, 667 Locally advanced, 867 Recurrent, 451
Adjuvant chemotherapy, 829 Recurrent, 463 Cervical carcinoma, 457
Adolescents, 991 Brookhaven Medical Research Reactor Cervix
Advanced stage, 67 (BMRR), 1149, 1167 Cancer, 335
Air gap, 741 BSH, 1107 Carcinoma, 277, 499, 1243
a-difluoromethylornithine (DFMO), 891 Biodistribution, 1175 Chelate, 1257
Amphotericin, 883 Pharmacokinetics, 1175 Chemotherapy, 77, 355, 363, 431, 583, 683,
Anal cancer, 189 Toxicology, 1175 867
Analysis Bulky endocervical cancer, 113 Adjuvant, 829
Cost benefit, 773 Busulfan, 883 Concurrent, 213
Image, 505 Children, 381
Video image, 921 CIS, 251
Antenna C Cis-DDP, 899
Insulated, 673 Cisplatin, 531, 1251
Theory, 673 Plus irradiation, 761
Anthropomorphic phantom, 731 Calculation of dose, 749 Classical, 613
Antibody, 1257 Californium-252, 703 Clonogenic myeloma progenitors, 877
ARRO 1992 survey, 1267 Caloric restriction, 641 Coaxial sleeve, 673
Assay(s) Cancer, 891 Collimator(s), 1167
Microcolony, 667 Anal, 189 Multileaf, 723
Predictive, 415 Bile duct, 945 Colon epithelium, 899
Asymmetric jaws, 753 Brachytherapy combined modality treat- Colorectal carcinoma, 349
ment of bile duct, 945 Combined modality(ies), 761, 945, 1029
B Breast, 285, 387, 395 Therapy, 77, 127, 563, 683, 1251
Bulky endocervical, 113 Compensation, 723
Cervical, 451 Complications, 113, 597, 1243
Beam Cervix, 335 Split course, 349
Epithermal neutron, 1149 Early breast, 1235 Compression of spinal cord, 605
Photon, 979 Endobronchial, 589 Computed tomography, 277
Beta ray, 101 Gastrointestinal, 439 Computer
Bile duct cancer, 945 Head and neck, 699, 847, 1025 Control, 1219
Brachytherapy combined modality treat- Intraductal, 105 Model, 673
ment, 945 Limited stage small cell lung, 355 Computerized tomography (CT), 93
Biopsy of prostate, 17 Locally advanced breast, 867 Planning, 731
Bladder and rectal dose, 277 Lung, 575, 589 Concomitant chemoradiotherapy, 1251
Blood-brain barrier, 1067 Nonsmall cell lung, 583, 1251 Concurrent
Bone, 363 Pancreatic, 207 Chemotherapy, 213
Bone-marrow Pediatric, 85 Radiochemotherapy, 1243
Transplant, 883 Prostate, 33, 39, 47, 151, 263, 303, 821, Conformal, 471
Transplantation, 343 1029 Radiotherapy, 1219
Boron, 1061, 1113, 1121, 1135, 1143 Recurrent cervical, 451 Therapy, 723
Determination techniques, 1175 Rectal, 597 Conformal three-dimensional (3-D)
Neutron capture therapy (BNCT), 1067, Recurrent breast, 463 Radiation therapy, 55
1079, 1089, 1099, 1107, 1121, 1135, Canine(s), 415 Radiotherapy, 267
1143, 1149, 1157, 1175, 1183, 1189, Tumors, 649 Conservative surgery, 105
1203 Capture therapy, 1061 Control
Boronated Carbogen, 145 Computer, 1219
Amino acids, 1203 Carcinoma(s) Local, 7, 163
Nucleosides, 1203 Cervical, 457 Tumor, 113
Nucleotides, 1203 Cervix, 277, 499, 1243 Cord
Peptides, 1203 Colorectal, 349 Spinal, 1107
Boronophenylalanine, 1089 Ductal in situ, 105 Vocal, 251
Brachytherapy, 113, 151, 171, 189, 247, 263, Endometrial, 349 Coronary artery, 1235
335, 499, 699, 703, 953, 971, 985 In situ (CIS), 251 Correction(s)
Combined modality treatment of bile Metastatic gastric, 711 Heterogeneity, 953
duct cancer, 945 Nasopharyngeal, 991 Inhomogeneity, 731
High dose rate, 589, 1243 Prostate, 7, 55, 67 Cost benefit analysis, 773
Interstitial, 221 Prostatic, 23, 985 Cutaneous T-cell lymphoma, 829
Intraluminal, 711 Squamous cell, 213, 221 Cyclin B, 135
Pulsed, 667 Cardiovascular disease, 1235 Cyclophosphamide, 829
XIX
Cyclosporine, 883 Extracorporeal photoimmunotherapy, 829 Human(s), 415, 425
Cytokines, 1029 Eye tumors, 101 Cell lines, 913
Myeloma cell lines, 877
F Hycanthone, 207
D Hyperfractionation, 213, 431
Hyperglycemia, 935
Factor(s) Hyperthermia, 151, 163, 171, 415, 425, 673
Deoxyribonucleic acid (DNA), 821 Dose effect, 563 Interstitial, 189
Diagnostic imaging, 1229 Growth, 445, 621 Sensitization, 935
Diarrhea, 905 Heat shock transcription, 179 Hypofractionation, 847
Disease Prognostic, 229 Hypoxia, 145, 661
Cardiovascular, 1235 Technical, 811 Markers, 649, 921
Hodgkin’s, 77, 93, 445, 683 Fast neutron radiotherapy, 1135 Tumor, 649, 921
Ischemic heart, 1235 Fibrosis, 621 Hypoxic cell, 201
Pediatric Hodgkin’s, 85 Field
Distant metastases, 7, 387 Abuttment, 741 I
Dogs, 1099 Matching, 753
Dose(s), 945 Filgrastim (G-CSF), 445
Absorbed, 1143 5-fluorouracil, 127, 439 ICRU reference volume, 499
Bladder and rectal, 277 Flow cytometry, 821 Image
Calculation, 749 Follicular mucinosis, 829 Analysis, 505
Criteria, 1143 Fraction spacing, 633 Fusion, 1229
Effect factor, 563 Fractionated Imaging
Escalation, 55 Irradiation, 145 Diagnostic, 1229
Heterogeneity, 971 Radiotherapy, 563 Magnetic resonance, 415
Intensity, 761 Fractionation, 343 On-line, 1017
Prescription, 1157 Portal, 1017
Reference level, 515 Immunohistochemistry, 921
G
Total, 583 Implant
Volume histogram(s), 515, 575 Gynecologic, 277
Dose rate Temporary, 719
Gastrointestinal cancer, 439
High, 335 Vaginal-template, 457
Gene induction, 661
High Ir-192, 711 Incidence of cataract, 343
Gentamicin, 883
Instantaneous, 343 Incomplete repair model, 667
Giant migrating contraction, 905
Low, 335, 667 Infradiaphragmatic, 683
Glioblastoma, 1061
Dosimetry, 505, 953, 979 Inhomogeneity correction, 731
Multiforme, 1175
In vivo, 285 In situ
Glioma, 247, 405, 1113, 1183
Neutron, 1149 Carcinoma, 251
Unverified, 405
Thermoluminescence, 731 Ductal carcinoma, 105
Globe-sparing treatment, 857
Doxorubicin, 829 Instantaneous dose rate, 343
Glottic, 251
Ductal carcinoma in situ (DCIS), 105 Insulated antenna, 673
Glucose regulated protein 78, 661
Interleukin 1, 761
Growth, 85
Interstitial, 673
Factor, 445, 621
Brachytherapy, 221
G2 delay, 135
Hyperthermia, 189
Gynecologic implant, 277
Iridium-192, 67
Early breast cancer, 1235 RF, 151
Eccentric core, 1143 H Intracavitary, 673
Effect(s) Therapy, 277
Acute, 667 Intracerebral melanoma, 1079
Late, 85, 847 Hazard rates, 39 Intracranial germ cell tumors, 229
Long-term, 1235 Head and neck, 731, 891 Intraductal cancer, 105
Skin and eye radiation, 1089 Cancer, 699, 847, 1025 Intraluminal brachytherapy, 711
Electrical control activity, 905 Neoplasms, 213 Intraoperative radiotherapy, 201
Electron Heat resistance, 179 Intrinsic cellular radiosensitivity, 913
Algorithm, 731 Heat shock proteins (HSP), 179, 425 In vivo, 667
Arc therapy, 297 HSC 70, 179, 425 Dosimetry, 285
Beams, 741 HSP 28, 179 lodine-125 implantation, 7
Boost, 1025 HSP 70.1, 179 Iridium-192 (Ir-192), 719
Cone, 1025 HSP 70.2, 179 High dose rate, 711
ELISA, 649 Heat shock transcription factor, 179 Interstitial, 67
Endemic Africa, 613 Heavy charged particles, 257 Irradiation, 105, 451
Endobronchial cancer, 589 Height Cisplatin plus, 761
Endometrial carcinoma, 349 Impairment, 85 External beam, 39
Enhancement, 201 Sitting, 85 Fractionated, 145
EORTC QLQ-C30, 847 Standing, 85 Light, 463
Ependymoma, 381 Helium ions, 257 Prostate, 267
Epidemic Kaposi’s sarcoma, 613 Hemoglobinopathy, 605 Time, 1143
Epithermal neutron beam, 1149 Heterogeneity Total body, 343, 1099
Errors of localization and treatment delivery, Corrections, 953 Ischemic heart disease, 1235
493 Dose, 971 Isoeffect formulae, 633
Etanidazole, 119, 201 High dose rate (HDR), 171, 247, 335
External beam Brachytherapy, 589, 1243 K
Irradiation, 39 Iridium-192, 711
Therapy, 979 HIV, 1113
Extracellular matrix, 621 Hodgkin’s disease, 77, 93, 445, 683 Kinetics, 23, 891
XX
Nausea, 905 Probability
Neoplasm(s), 921 Normal tissue complication, 575
Brain, 431 Tumor control, 515, 971
L-arginine antagonists, 1029 Head and neck, 213 Prognosis, 387, 839
Larynx, 251, 467 Nephropathy, 883 Prognostic factors, 229
Late effects, 85, 847 Neuroma, 803 For prostate cancer, 33
Levamisole, 439 Neutron(s), 47, 703, 913, 1061, 1121 Proliferation, 891
Light irradiation, 463 Dosimetry, 1149 Prostate, 81 1
Limited stage small cell lung cancer, 355 Epithermal beam, 1149 Biopsy, 17
Linac radiosurgery, 803 Thermal, 1107 Carcinoma, 7, 55, 67
Linear accelerator, 471, 481, 1001 Neutron capture, 1135, 1143 Irradiation, 267
Local control, 7, 163 Therapy (NCT), 1113, 1167 Specific antigen, 23, 55, 821
Localization, 1017 Nicotinamide, 145 Prostate cancer, 33, 39, 47, 151, 263, 303,
Treatment delivery errors and, 493 Nitroimidazoles, 921 821, 1029
Locally advanced breast cancer, 867 Nodal recurrence, 387 Prognostic factors for, 33
Long-term effects, 1235 NonHodgkin’s lymphoma, 1 19 Prostatic carcinoma, 23, 985
Low dose Nonsmall cell lung cancer (NSCLC), 583, Protein(s)
Radiation, 641 1251 Glucose regulated (78), 661
Rate (LDR), 335, 667 Nonspecific dermatitis, 829 Heat shock, 179, 425
Lung, 621 Normal bone marrow radiosensitivity, 877 Over-expression, 395
Radiation-induced damage, 633 Normal tissue Pterygium, 101
Lung cancer, 575, 589 Complication probability, 575 Pulsed brachytherapy, 667
Limited stage small cell, 355 Tolerance, 1099, 1157
Nonsmall cell, 583, 1251 Toxicity, 583 Q
Lymph node(s) Nucleosides, 1113
Metastases, 7 Boronated, 1203
Paraaortic, 451 Nude rat model, 1079 Quality assurance, 285, 773, 1001
Supraclavicular, 387 Quality of life, 847
Lymphoma, 363 Questionnaires, 847
Cutaneous T-cell, 829 O
NonHodgkin’s, 119 R
Lymphomatoid papulosis, 829
On-line imaging, 1017
Open table-top device, 597 Racetrack microtron, 1219
M
Oral mucositis, 693 Radiation, 127, 163, 531, 621, 839, 883, 891,
Prevention and treatment of, 693 899, 945, 1029
Oral psoralen and total skin UVA light Induced lung damage, 633
Magnetic resonance imaging (MRI), 415
Distortion, 1229 (PUVA), 829 Low dose, 641
Morbidity, 55
Magnetic resonance spectroscopy, 415
Malignant biliary obstruction, 711 Pneumonitis, 563
Sensitizer, 201, 207
Masses of extramedullary hemopoiesis, 605
Sickness, 905
Melanoma, 703, 1183
Skin and eye effects, 1089
Intracerebral, 1079
Pancreatic cancer, 207 Sources, 703
Meningioma, 257
Metastases, 797 Paraaortic lymph nodes, 451 Radiation therapy, 7, 85, 277, 285, 303, 373,
Paranasal sinus tumors, 857 381, 431, 445, 467, 613, 683, 693,
Distant, 7, 387
Pathogenesis, | 107 811, 821, 857, 979
Lymph node, 7
p-Boronophenylalanine (BPA), 1183 Three-dimensional conformal, 55
Spinal, 229
Pediatric, 77 Total skin electron beam, 829
Metastatic gastric carcinoma, 71 |
Cancer, 85 Radioimmunoglobulin therapy, 505
Mice, 899
Hodgkin’s disease, 85 Radioimmunotherapy, 119
Microcolony assay, 667
Microdosimetry, 1121 Phantom, 1143 Radiosensitivity, 613
Anthropomorphic, 731 Intrinsic cellular, 913
Mitomycin C, 127
MMC, 905 Pharmacokinetics, 1183 Normal bone marrow, 877
BSH, 1175 Radiosurgery, 523, 797, 803
Model
Photodynamic therapy, 463 Linac, 803
Computer, 673
Photon(s), 913 Stereotactic, 471, 481, 493, 1229
Incomplete repair, 667
Nude rat, 1079 Beam, 979 Radiotherapy, 47, 67, 77, 113, 251, 257, 355,
Pineal region tumors, 229 363, 405, 583, 605, 773, 847, 867,
Modulation of mouse mammary tumor, 641
Planning 991, 1017, 1235, 1251
Monitor setting, 749
Computerized tomography (CT), 731 Conformal, 1219
Monte Carlo simulation, 953
Three-dimensional (3-D) treatment, 857 Fast neutron, 1135
Morbidity, 811, 985, 1235
Radiation, 55 Treatment, 979, 1121, 1229 Fractionated, 563
Platinum drugs, 1029 Intraoperative, 201
Motility, 905
Ploidy, 821 Machine, 1219
Multileaf collimators, 723
Polyamines, 891 Postoperative, 597
Multiple myeloma, 877
Polymerase chain reaction, 179 Stereotactic, 1001, 1229
Mycosis fungoides, 829, 839
Portal imaging, 1017 Three-dimensional (3-D) conformal, 267
Myeloproliferative disorders, 605
Postirradiation, 17 Treatment planning, 515
Myelosuppression, 445
Postoperative radiotherapy (XRT), 597 Randomized trial, 207
Precision, 48 1 Rat, 1167
N Predictive assays, 415 9L gliosarcoma, 1067
Prevention and treatment of oral mucositis, Rate
693 High dose, 171, 247, 335
Nasopharyngeal carcinoma, 991 Primitive neuroectodermal tumors (PNET), Low dose, 335
Nasopharynx, 699, 991 431 Relapse, 303
XXI
RBE, 913 Temporary implant, 719 Canine, 649
Rectal cancer, 597 Testicular seminoma, 373 Eye, 101
Recurrent Thalassemic osteoarthropathy, 605 Hypoxia, 649, 921
Breast cancer, 463 Therapeutic gain, 761 Infiltrating lymphocytes, 641
Cervical cancer, 451 Therapy monitoring, 415 Intracranial germ cell, 229
Reference dose level, 515 Therapy, 1143 Markers, 33
Relapse, 303 Boron neutron capture, 1067, 1079, 1089, Modulation of mouse mammary, 641
Review, 1189 1099, 1107, 1121, 1135, 1143, 1149, Paranasal sinus, 857
1157, 1175, 1183, 1189, 1203 Perfusion, 1029
Capture, 1061 pH, 935
S
Combined modality, 77, 127, 563, 683, Pineal region, 229
1251 Primitive neuroectodermal, 431
Conformal, 723 Solid in mice, 127
Sarcoma(s)
Electron arc, 297 Suprasellar, 229
Epidemic Kaposi’s, 613
External beam, 979 Tumor control, 113
Soft tissue, 415
Intracavitary, 277 Probability (TCP), 515, 971
Schedule dependence, 761
Neutron capture, 1113 2-nitroimidazoles, 649
Sequelae, 163
Photodynamic, 463
Shaped field, 471
Radiation, 7, 85, 277, 285, 303, 373, 381,
Silicon diode measurements, 953
431, 445, 467, 613, 683, 693, 811, U
Sitting height, 85
821, 857, 979
Skin, 1099
Radioimmunoglobulin, 505
Eye radiation effects, 1089
Total skin electron beam radiation, 829 Ultrasound guidance, 263
Soft tissue sarcomas, 415
Thermal Unverified glioma, 405
Solid tumors in mice, 127
Distributions, 189
Sources of radiation, 703
Neutrons, 1107
Spinal cord, 1107
Thermoluminescence dosimetry, 731 V
Compression, 605
Thermometry, 151
Spinal metastases, 229
Thermotolerance, 171, 425
Spleen, 93
Three-dimensional (3-D) Vaginal
Splenomegaly, 93
Plans, 1009 Stenosis, 457
Split course complications, 349
Reconstruction image processing, 1009 Template implant, 457
Spontaneous fracture, 605
Treatment planning, 575, 857 Video image analysis, 921
Squamous, 891
Three-dimensional (3-D) conformal Vietnam, 773
Cell carcinoma(s), 213, 221
Radiation therapy, 55 Vocal cord, 251
SR 2508, 201
Radiotherapy, 267 Volume
SR 4233, 119, 145
Tirapazamine, 145 ICRU reference, 499
Staging, 839
Tissue concentrations, 531 Treatment, 499
Laparotomy, 683
Tomography Vomiting, 905
Standing height, 85
Computed, 277
Static field, 471
Computerized, 93
Stereotactic, 247, 797
Tonsil, 221 Ww
Radiosurgery, 471, 481, 493, 1229
Total
Radiotherapy, 1001, 1229
Body irradiation, 343, 1099
Strontium-90, 101
Dose, 583 Warm-water hyperthermia system, 189
Subdiaphragmatic, 683
Skin electron beam radiation therapy, 829 WR-2721, 899
Supraclavicular lymph nodes, 387
Toxicity of normal tissue, 583
Suprasellar tumors, 229
Transplantation of bone-marrow, 343
Surgery, 303
Treatment planning, 1121, 1229 xX
Conservative, 105
Radiotherapy, 515
Survival, 17, 163, 839
Three-dimensional (3-D), 575, 857
Swallowing, 467
Treatment X rays, 723
Breast, 297 Xenograft, 1257
T Globe-sparing, 857
Techniques, 753
Time, 1157 Y
Technical factors, 811 Volume, 499
Techniques TRIGA-II, 1143
Boron determination, 1175 Tumor(s) Ytterbium-169, 953
Treatment, 753 Brain, 531, 1167 Yttrium, 1257
XXII